NSF I-Corps™ Teams Award #2632220 · Team 4950 · National Cohort Fall #2, 2026
GAICo-D: Exploring Commercialization of Domain-Aware Generative AI Evaluation
Can our open-source GenAI results comparator, GAICo, become a product for high-stakes domains, starting with health? We are finding out by talking to the people who would use and buy it.
Recent Updates
- Upcoming Nov 19–20, 2026 - Lessons Learned presentation and video at the I-Corps closing sessions. The video will be posted below.
- Nov 2026 - Team at AIMed26 (Orlando, FL, Nov 11–13) to continue customer discovery interviews.
- Nov 2026 - 94 customer discovery interviews completed as of Nov 12, working toward the program's goal of 100+.
- Nov 2026 - Session 8 report-out on key partners, resources, and our path to the first $1M.
- Nov 2026 - Narrowed our focus to a single customer segment: urban health systems (Session 7).
- Oct 2026 - Interviewed attendees at Safe AI for Seniors (SAiS 2026), Oct 23.
- Oct 2026 - Started the NSF I-Corps national program with kickoff sessions on Oct 5–9, followed by weekly report-outs.
- Aug 2026 - Received an NSF I-Corps award, 2026–2027, to explore the technology transfer potential of the Generative AI evaluation tool (GAICo) for businesses (details) [GenAI, Domain Evaluation].
Lessons Learned Video
Coming soon. Our I-Corps Lessons Learned video will be posted here after the closing session on Nov 20, 2026.
Project Overview
This I-Corps project builds on an evaluation framework for comparing results from Generative Artificial Intelligence (GenAI) systems. Organizations are rapidly trying out Foundation Models (FMs) and Large Language Models (LLMs) to support complex data analyses in domains like health, finance, law, and chemical manufacturing. These models promise improved performance and flexibility across diverse recording modalities. However, practitioners today often resort to ad hoc, non-standardized scripts using their choice of metrics from a large available set. In preliminary work, we created a domain-independent approach for evaluating foundation model outputs across text, audio, and images, with standardized support for visualization and automation of downstream processing, called GAICo (Generative AI Results Comparator). We will now specialize it to industry domains to meet the growing demand for reliable, domain-aware evaluation tools as generative AI becomes embedded in high-stakes environments. Its long-term impacts include reducing user risks, improving accountability in AI deployment, and establishing a new standard for responsible AI evaluation.
This I-Corps project uses experiential learning, coupled with first-hand investigation of the industry ecosystem, to assess the translation potential of Generative AI for high-impact application domains. GenAI evaluation methods often treat all deviations from a reference as equivalent, which can hide domain-critical errors while overemphasizing trivial differences. GAICo was created from the need to compare GenAI results while training FMs in a previous NSF initiative, and has been widely downloaded. The new technology extends GAICo to application domains, starting with health, and is generalizable to others. In health, focusing on brain science, our scope includes biosignals such as electroencephalography (EEG), electrocardiography (ECG), and eye tracking (ET). GAICo-Health will provide detailed evaluation of GenAI outputs through both reference-based and reference-free visualizations, metrics, and insights. The new system compares generated AI results in a domain-aware manner and produces severity-aware scores, visual explanations, and action reports. The approach integrates domain ontology, severity-weighted scoring, stage-level error attribution, escalation estimation, domain-specific visualization, and action dispatch in one evaluation workflow.
Our current business thesis (Session 8, Nov 12, 2026)
We help urban healthcare organizations decide whether GenAI applications are ready for deployment through health-specific testing of accuracy and reliability. Our suite targets a minimum 35% reduction in staff hours spent implementing and running evaluations, compared with the user's existing process.
Funding Information
- NSF, 2026–2027, I-Corps: Explore commercialization of GenAI result comparison specific to an application domain (Award #2632220) [GenAI, Evaluation, Health, Commercialization].
- Builds on NSF, 2025–2027, EAGER: Demonstrating a Compact Foundation Model for Planning-Like (PL) Tasks for Next Generation Trusted Applications (Award #2454027), where GAICo was first developed.